<DOC>
	<DOC>NCT01543139</DOC>
	<brief_summary>This proposed research is aimed to investigate the efficacy and safety of the creatine and cytidine augmentation in treating bipolar depression and to evaluate changes in relevant brain biochemical metabolism using magnetic resonance spectroscopy.</brief_summary>
	<brief_title>Trial of Combined Cytidine and Creatine in the Treatment of the Bipolar Depression</brief_title>
	<detailed_description />
	<mesh_term>Depression</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Valproic Acid</mesh_term>
	<criteria>Men and women aged between 18 and 65 Diagnosis of bipolar depression as assessed by the Structured Clinical Interview for DSMIV (SCIDIV) Individuals who provided written consent for participation Present or past use of drugs for bipolar depression Presence of any major physical or neurological illness (e.g., head trauma, epilepsy, seizure, stroke, cerebral tumor, multiple sclerosis, cerebrovascular disease, narrowangle glaucoma, drug hypersensitivity, etc.) Diagnosis of any Axis I disorder other than bipolar disorder or presence of symptoms requiring hospitalization Presence of borderline personality disorder or antisocial personality disorder Presence of alcohol or drug dependence Intelligence quotient below 80 Contraindications to magnetic resonance imaging (e.g., pacemaker implantation, claustrophobia, etc.) Use of psychoactive medications that may affect brain imaging findings Women who are pregnant, breastfeeding, or planning pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2012</verification_date>
</DOC>